BRPI0616374B8 - forma i do sal de fosfato de um composto pirrol substituído 2-indolinona, composição farmacêutica, usos e método de preparação da forma i - Google Patents
forma i do sal de fosfato de um composto pirrol substituído 2-indolinona, composição farmacêutica, usos e método de preparação da forma iInfo
- Publication number
- BRPI0616374B8 BRPI0616374B8 BRPI0616374A BRPI0616374A BRPI0616374B8 BR PI0616374 B8 BRPI0616374 B8 BR PI0616374B8 BR PI0616374 A BRPI0616374 A BR PI0616374A BR PI0616374 A BRPI0616374 A BR PI0616374A BR PI0616374 B8 BRPI0616374 B8 BR PI0616374B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- indolinone
- phosphate salt
- polymorphs
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Abstract
formas de sal sólido para um pirrol substituído 2-indolinona, composição farmacêutica compreendendo as mesmas, método para modulação de atividade catalítica de proteína quinase, proteína quinase, métodos para preparação de cristais e de polimorfos e uso. a presente invenção refere-se a formas de sal sólido de um composto 3-pirrol substituído 2-indolinona, (2-pirrolidina-1-ii-etil)-amida de ácido 5-[5-flúor-2-oxo-1 ,2-di-hidro-indol-(3z)-ilidenometil]-2 ,4-dimetil-1h-pirrol-3- carboxílico. também refere-se a polimorfos do sal fosfato da amida. a invenção ainda refere-se ao uso dos sais e polimorfos no tratamento de distúrbios relacionados com proteína quinase.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71858605P | 2005-09-19 | 2005-09-19 | |
| US60/718,586 | 2005-09-19 | ||
| PCT/IB2006/002506 WO2007034272A1 (en) | 2005-09-19 | 2006-09-08 | Solid salt forms of a pyrrole substituted 2-indolinone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0616374A2 BRPI0616374A2 (pt) | 2011-06-21 |
| BRPI0616374B1 BRPI0616374B1 (pt) | 2020-05-12 |
| BRPI0616374B8 true BRPI0616374B8 (pt) | 2021-05-25 |
Family
ID=37626412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0616374A BRPI0616374B8 (pt) | 2005-09-19 | 2006-09-08 | forma i do sal de fosfato de um composto pirrol substituído 2-indolinona, composição farmacêutica, usos e método de preparação da forma i |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20080275101A1 (pt) |
| EP (2) | EP1928858B1 (pt) |
| JP (2) | JP4519114B2 (pt) |
| KR (1) | KR101050906B1 (pt) |
| CN (2) | CN101287724B (pt) |
| AR (1) | AR056521A1 (pt) |
| AU (1) | AU2006293644B2 (pt) |
| BR (1) | BRPI0616374B8 (pt) |
| CA (1) | CA2621569C (pt) |
| CY (1) | CY1109326T1 (pt) |
| DE (1) | DE602006008015D1 (pt) |
| DK (1) | DK1928858T3 (pt) |
| ES (1) | ES2328407T3 (pt) |
| HK (1) | HK1125101A1 (pt) |
| IL (1) | IL189590A0 (pt) |
| MX (1) | MX2008002415A (pt) |
| NO (1) | NO20080866L (pt) |
| NZ (1) | NZ566033A (pt) |
| PL (1) | PL1928858T3 (pt) |
| PT (1) | PT1928858E (pt) |
| RU (1) | RU2399619C2 (pt) |
| SI (1) | SI1928858T1 (pt) |
| TW (1) | TWI310766B (pt) |
| WO (1) | WO2007034272A1 (pt) |
| ZA (1) | ZA200801431B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1928858T1 (sl) | 2005-09-19 | 2009-10-31 | Pfizer Prod Inc | Trde solne oblike s pirolom substituiranega 2-indolinona |
| US20100189791A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| EP2545034A1 (en) | 2010-03-10 | 2013-01-16 | Synthon B.V. | A process for amidation of pyrrole carboxylate compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6574293B1 (en) | 1998-10-28 | 2003-06-03 | Ericsson Inc. | Receivers and methods for reducing interference in radio communications |
| US20020010203A1 (en) * | 1999-12-22 | 2002-01-24 | Ken Lipson | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
| NZ520640A (en) * | 2000-02-15 | 2005-04-29 | Upjohn Co | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| US6797725B2 (en) * | 2001-04-09 | 2004-09-28 | Sugen, Inc. | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| PT3168218T (pt) | 2001-08-15 | 2019-01-11 | Pharmacia & Upjohn Co Llc | Um cristal compreendendo um sal de ácido l-málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3h-indol- 3-ilideno)metil]-2,4-dimetil-1h-pirrol-3-carboxamida para utilização como um medicamento |
| US7119209B2 (en) * | 2002-02-15 | 2006-10-10 | Pharmacia & Upjohn Company | Process for preparing indolinone derivatives |
| US7452913B2 (en) * | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
| US20040209937A1 (en) * | 2003-02-24 | 2004-10-21 | Sugen, Inc. | Treatment of excessive osteolysis with indolinone compounds |
| US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
| SI1928858T1 (sl) | 2005-09-19 | 2009-10-31 | Pfizer Prod Inc | Trde solne oblike s pirolom substituiranega 2-indolinona |
-
2006
- 2006-09-08 SI SI200630386T patent/SI1928858T1/sl unknown
- 2006-09-08 PL PL06795470T patent/PL1928858T3/pl unknown
- 2006-09-08 KR KR1020087006545A patent/KR101050906B1/ko active IP Right Grant
- 2006-09-08 EP EP06795470A patent/EP1928858B1/en active Active
- 2006-09-08 MX MX2008002415A patent/MX2008002415A/es active IP Right Grant
- 2006-09-08 AU AU2006293644A patent/AU2006293644B2/en active Active
- 2006-09-08 CA CA2621569A patent/CA2621569C/en active Active
- 2006-09-08 CN CN2006800345053A patent/CN101287724B/zh active Active
- 2006-09-08 PT PT06795470T patent/PT1928858E/pt unknown
- 2006-09-08 CN CN201310478975.0A patent/CN103601720B/zh active Active
- 2006-09-08 BR BRPI0616374A patent/BRPI0616374B8/pt active IP Right Grant
- 2006-09-08 NZ NZ566033A patent/NZ566033A/en unknown
- 2006-09-08 WO PCT/IB2006/002506 patent/WO2007034272A1/en active Application Filing
- 2006-09-08 US US12/067,242 patent/US20080275101A1/en not_active Abandoned
- 2006-09-08 RU RU2008109959/04A patent/RU2399619C2/ru not_active IP Right Cessation
- 2006-09-08 DE DE602006008015T patent/DE602006008015D1/de active Active
- 2006-09-08 ES ES06795470T patent/ES2328407T3/es active Active
- 2006-09-08 EP EP09165944A patent/EP2112148A1/en not_active Withdrawn
- 2006-09-08 DK DK06795470T patent/DK1928858T3/da active
- 2006-09-15 JP JP2006250347A patent/JP4519114B2/ja active Active
- 2006-09-18 TW TW095134445A patent/TWI310766B/zh not_active IP Right Cessation
- 2006-09-19 AR ARP060104101A patent/AR056521A1/es not_active Application Discontinuation
-
2008
- 2008-02-18 IL IL189590A patent/IL189590A0/en unknown
- 2008-02-18 NO NO20080866A patent/NO20080866L/no not_active Application Discontinuation
- 2008-09-12 ZA ZA200801431A patent/ZA200801431B/xx unknown
-
2009
- 2009-03-16 HK HK09102463.5A patent/HK1125101A1/xx unknown
- 2009-08-20 CY CY20091100887T patent/CY1109326T1/el unknown
- 2009-12-10 JP JP2009279987A patent/JP2010090152A/ja active Pending
-
2012
- 2012-02-06 US US13/367,009 patent/US8987320B2/en active Active
-
2015
- 2015-02-12 US US14/620,835 patent/US9290479B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
| HRP20150704T1 (hr) | Derivati piperidinona kao mdm2-inhibitori za lijeäśenje raka | |
| WO2007042786A3 (en) | 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors | |
| BR112015010102A2 (pt) | compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifnalfa | |
| UY32062A (es) | Inhibidores de beta-secretasa | |
| ATE486872T1 (de) | Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs | |
| EA201171333A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| ATE489088T1 (de) | N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid- derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration | |
| GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
| EA201100030A1 (ru) | Пиразольные соединения 436 | |
| BRPI0813499B8 (pt) | compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos | |
| CL2008002354A1 (es) | Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; composición y combinacion farmacéutica; y su uso para tratar la hepatitis c. | |
| BRPI0910832B8 (pt) | derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos. | |
| BRPI0916735B8 (pt) | compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos | |
| EA201290121A1 (ru) | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов | |
| EA201070164A1 (ru) | Твердый препарат, включающий алоглиптин и гидрохлорид метформина | |
| WO2007087283A3 (en) | Thiophene-carboxamides useful as inhibitors of protein kinases | |
| BRPI0612189A2 (pt) | composto, composiÇço farmacÊutica, mÉtodo para ligar receptores opiàides | |
| EA200970532A1 (ru) | Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола | |
| EA200800017A1 (ru) | Алкилхинолиновые и алкилхиназолиновые модуляторы киназы | |
| EA201071409A1 (ru) | Новые соли (4-{[(5-{[(3-хлорфенил)метил]окси}-2-метилфенил)карбонил]амино}-3-метилфенил)уксусной кислоты | |
| EA200800015A1 (ru) | Аминопиримидины в качестве модуляторов киназы | |
| WO2008042282A3 (en) | Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators | |
| DK1885187T3 (da) | Fremgangsmåde til behandling af lægemiddelresistent cancer | |
| WO2009012375A3 (en) | Squarate kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: APRESENTE O DEPOSITANTE NOVAS VIAS DAS FOLHAS DOS DESENHOS, SEM CORES , CONFORME DETERMINA ATO NORMATIVO NO 127 DE 05/03/1997 ITEM 15.1.4.1B. |
|
| B25A | Requested transfer of rights approved |
Owner name: PAH USA 15 LLC (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: ZOETIS P LLC (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: ZOETIS SERVICES LLC (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: ZOETIS SERVICES LLC (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/09/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |